- Home
- PMCB vs MRKR Comparison
PMCB vs MRKR Comparison
Compare PMCB & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- MRKR
- Stock Information
- Founded
- PMCB 1996
- MRKR N/A
- Country
- PMCB United States
- MRKR United States
- Employees
- PMCB N/A
- MRKR N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- MRKR Health Care
- Exchange
- PMCB Nasdaq
- MRKR Nasdaq
- Market Cap
- PMCB 11.4M
- MRKR 11.8M
- IPO Year
- PMCB N/A
- MRKR N/A
- Fundamental
- Price
- PMCB $1.06
- MRKR $1.19
- Analyst Decision
- PMCB
- MRKR Strong Buy
- Analyst Count
- PMCB 0
- MRKR 3
- Target Price
- PMCB N/A
- MRKR $13.17
- AVG Volume (30 Days)
- PMCB 11.3K
- MRKR 38.3K
- Earning Date
- PMCB 03-17-2025
- MRKR 05-19-2025
- Dividend Yield
- PMCB N/A
- MRKR N/A
- EPS Growth
- PMCB N/A
- MRKR N/A
- EPS
- PMCB 1.29
- MRKR N/A
- Revenue
- PMCB N/A
- MRKR $6,591,080.00
- Revenue This Year
- PMCB N/A
- MRKR N/A
- Revenue Next Year
- PMCB N/A
- MRKR N/A
- P/E Ratio
- PMCB $0.85
- MRKR N/A
- Revenue Growth
- PMCB N/A
- MRKR 99.06
- 52 Week Low
- PMCB $1.03
- MRKR $0.95
- 52 Week High
- PMCB $2.42
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- PMCB 36.21
- MRKR 50.23
- Support Level
- PMCB $1.08
- MRKR $1.10
- Resistance Level
- PMCB $1.39
- MRKR $1.29
- Average True Range (ATR)
- PMCB 0.10
- MRKR 0.08
- MACD
- PMCB 0.00
- MRKR 0.01
- Stochastic Oscillator
- PMCB 0.00
- MRKR 58.10
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.